Clarity Pharmaceuticals launched “Insight”, a quarterly newsletter focussed on the latest news in the imaging industry.
The first issue explored Genentech’s anti-C-MET Phase III trial, and how imaging might have changed the outcome, and looked at how imaging has been used to successfully support the ZEPHIR trial.
1. Read Issue 1 here
2. Read Issue 2 here
3. Read Issue 3 here
4. Read Issue 4 here
5. Read Issue 5 here
6. Read Issue 6 here
Subscribe below to get the next issue delivered to your inbox.
